- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 89 publications
- Percutaneous Coronary Intervention , 54 publications
- Purinergic P2Y Receptor Antagonists , 47 publications
- Clopidogrel , 40 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
136 publications
2025
Switching from cangrelor to oral P2Y12 inhibitors: a focused review on drug-drug interactions.
Expert opinion on drug metabolism & toxicology
PubMed • Publisher's site2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD
JACC: Basic to Translational Science
PubMed • Publisher's site2024
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis.
European heart journal. Cardiovascular pharmacotherapy
PubMed • Publisher's site2024
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.
Journal of the American Heart Association
PubMed • Publisher's site2024
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.
Minerva cardiology and angiology
PubMed • Publisher's site